PYC Therapeutics (ASX:PYC) has has been approved to escalate doses of its drug candidate VP-001, treating Retinitis Pigmentosa 11, in a second patient cohort. Dosages will be lifted to 75 micrograms (mcg). The second cohort comprises patients part of the company’s Multiple Ascending Dose (MAD) study which runs alongside a Single Ascending Dose (SAD) study. Both Phase 1/2 studies are ongoing. A safety review body ticked off on higher doses for the MAD group on Tuesday. PYC reports that patients already doses with VP-001 in either stage of studies so far have shown “disease progression arrested …